Canada DNA Vaccine Market to Reach $57.65 Million by 2035

Canada DNA vaccine market was valued at $40.99 million in 2025 and is projected to reach $57.65 million by 2035, registering a CAGR of 3.5% during the forecast period from 2026 to 2035. The market is being shaped by notable clinical activity and expanding trial infrastructure, which together are elevating the market’s visibility and potential. A central catalyst is the Phase 1/2 clinical programme for Covigenix VAX-002, a plasmid DNA booster vaccine targeting circulating SARS-CoV-2 variants, which received Health Canada approval to initiate human studies in 2024. The trial is actively progressing, with the first participant dosed across multiple provinces and enrolment completed in the Phase 1 cohort. This clinical momentum is enhancing confidence among stakeholders, supporting broader engagement from biotechnology firms and clinical research organisations. The growing body of domestic clinical experience is strengthening Canada’s capacity to evaluate, optimise, and potentially adopt DNA vaccine solutions. As a result, the market is increasingly defined by tangible, regulated clinical progress within Canada’s health ecosystem.

Browse the full report description of “Canada DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, and Human DNA Vaccine), by Technology (Plasmid DNA Vaccines Technology, and Plasmid DNA Delivery Technology), by Application (Oncology, Infectious Diseases, and Others), Forecast Period 2026-2035” at https://www.omrglobal.com/industry-reports/canada-dna-vaccines-market

• Health Canada approved in 2024 to initiate the Phase 1/2 clinical trial (NCT06436911) of the Covigenix VAX-002 plasmid DNA booster vaccine, a key regulatory milestone for DNA vaccines in Canada.
• First participant dosing in the Covigenix VAX-002 trial was reported in August 2024, marking the beginning of human clinical evaluation in the Canadian population.
• Phase 1 enrolment for the Covigenix VAX-002 study was completed across 12 sites in Alberta, Ontario, Quebec, and Nova Scotia, signalling strong clinical uptake and execution capability.
• The Phase 1 segment targets dose optimisation with 50 participants, providing precise data on safety and initial immune response metrics in Canadian subjects.
• The Phase 2 portion of the study aims to evaluate the safety and immunogenicity of the optimal dose in 250 participants, indicating a planned expansion of trial scope.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Type
  • Technology
  • Application
• Competitive Landscape –Aldevron, LLC, Applied DNA Sciences, Inc., Entos Pharmaceuticals, Inc., GeneOne Life Science, Inc., Inovio Pharmaceuticals, Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Canada DNA Vaccine Market Report Segment

By Type

• Animal DNA Vaccine
• Human DNA Vaccine

By Technology

• Plasmid DNA Vaccines Technology
• Plasmid DNA Delivery Technology

By Application

• Oncology
• Infectious Diseases
• Others

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/canada-dna-vaccines-market